Collaboration combines Lunit's AI expertise with Agilent's diagnostic leadership to revolutionize biomarker testing and enhance precision medicine capabilities
Clinical evidence has consistently highlighted lacosamide’s efficacy and safety.
Keytruda Qlex is the first and only subcutaneously administered immune checkpoint inhibitor that can be given by a health care provider in as little as one minute
The goal is to deliver greater value to customers, doctors, and the broader healthcare ecosystem
Funding supports development of first-in-class pan-ROCK inhibitor ROC-101 through Phase 2a clinical testing
This predictive technology empowers people with diabetes to take preventive action before complications arise
Merck opens first climate-neutral manufacturing facility in Ireland
Subscribe To Our Newsletter & Stay Updated
